Stock Analiz

Hyperion Defi, Inc. HYPD

Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026

$2.58Market cap $40M
Open the interactive analysis →

Hyperion Defi, Inc. (HYPD) is a healthcare company listed in the US with a market value of about $40M. In the twelve months to September 30, 2026 it had revenue of $2M and net income of $40M, a net margin of 2075.4%.

Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is value (3/5); the weakest is track record (0/5).

Key numbers: a P/E of 1.0, 5-year revenue growth of -16% a year, a 5-year average ROIC of -65%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 30% above the current price.

About Hyperion Defi

Hyperion Defi is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2018. Revenue went from $2M in 2020 to $813455 in 2025, a decline of about 16.5% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 1089% over three years (dilution for shareholders). It spends 235% of revenue on research and development.

Score: 1.6 / 5

Value3/5
Future growth3/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • Price below intrinsic value (DCF, moderate assumptions)
  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/FCF below 20
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year
  • 5-year average ROIC above 12%
  • Profitable 5 years in a row

Valuation

P/E (TTM)1.0
Forward P/E1.5
P/FCF—
P/S20.9
P/B0.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price+30%

Growth and quality

Revenue growth (1 yr)1318.8%
Revenue growth (5 yrs, per year)-16.5%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-203100.0%
ROIC (5-yr avg.)-64.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$2M$813455$57336$3787—$14M$2M————
Net income$40M-$45M-$50M-$27M-$28M-$13M-$20M-$21M-$17M-$5M-$4M
Free cash flow——-$30M-$27M-$26M-$22M-$7M-$19M-$13M-$5M-$3M
EPS (diluted)$2.64$-3.13$-19.94$-17.72$-22.13$-13.07$-25.07$-39.20$-48.53$-58.40$-41.60
Net margin2075.4%-5570.6%-86888.6%-719900.0%—-91.3%-988.5%————
ROIC—-73.6%—-75.9%-73.2%-36.8%-99.2%-143.4%-80.8%-79.7%-92.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $9.82, 281% above the current price; targets range from $8.45 to $11.20; the consensus rating is “Strong buy”; expected EPS is $5.78 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is Hyperion Defi’s P/E ratio?

About 1.0, based on the last twelve months of diluted earnings per share (forward P/E about 1.5).

Is Hyperion Defi stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 30% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Hyperion Defi pay a dividend?

Not currently.

Is Hyperion Defi a good stock to buy?

We do not give buy or sell advice. Hyperion Defi scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.